Drug Type Small molecule drug |
Synonyms Baycuten N |
Target |
Action inhibitors, agonists |
Mechanism CYP51A1 inhibitors(Cytochrome P450 51 inhibitors), GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H31FO6 |
InChIKeyAKUJBENLRBOFTD-RPRRAYFGSA-N |
CAS Registry1177-87-3 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Bacterial Infections | Phase 3 | Brazil | 11 Jun 2019 | |
| Blister | Phase 3 | Brazil | 11 Jun 2019 | |
| Coinfection | Phase 3 | Brazil | 11 Jun 2019 | |
| Dermatitis, Atopic | Phase 3 | Brazil | 11 Jun 2019 | |
| Dermatitis, Contact | Phase 3 | Brazil | 11 Jun 2019 | |
| Dermatitis, Seborrheic | Phase 3 | Brazil | 11 Jun 2019 | |
| Eczema, Dyshidrotic | Phase 3 | Brazil | 11 Jun 2019 | |
| Erythema | Phase 3 | Brazil | 11 Jun 2019 | |
| Inflammation | Phase 3 | Brazil | 11 Jun 2019 | |
| Intertrigo | Phase 3 | Brazil | 11 Jun 2019 |





